Marine Compounds Show Promise Against Cancer Drug Resistance
Advanced computer simulations highlight four natural marine molecules that bind tightly to drug-pumping cellular proteins, though laboratory testing is still needed.
When cancer cells develop the ability to pump out life-saving chemotherapy drugs before they can work, patients face a severe hurdle known as multidrug resistance. Researchers are now zeroing in on marine natural products as potential keys to disarming this cellular defense system by targeting a specific protein transporter.
Screening Over 14,000 Marine Compounds
Scientists investigated more than 14,000 marine-derived compounds using advanced computer simulations to find candidates that could block the breast cancer resistance protein, a cell surface gatekeeper that normally shields healthy tissues from toxins by pushing them out. In cancer cells, however, this same protein works overtime to eject chemotherapy agents, rendering treatments ineffective and leaving patients with fewer clinical options.
To identify the most promising molecular structures, the research team used docking software to test how well individual marine compounds fit into the binding pocket of the breast cancer resistance protein. The computational study, published in Royal Society open science, evaluated thousands of candidates against a reference inhibitor molecule known as BWQ/MZ29.
Four Standout Molecules Revealed Strong Stability
Out of the massive library, initial screenings flagged hundreds of potential binders, which were subsequently narrowed down through increasingly rigorous tests. The team subjected top candidates to 200 nanoseconds of molecular dynamics simulations, tracking how the molecules behaved when nestled inside the protein structure.
Four particular marine compounds emerged with exceptionally strong predicted binding energies, significantly outperforming the reference molecule. These included two structurally complex entities, namely UMHMNP164176323 and UMHMNP164176312, alongside two marine sponge metabolites known as sarasinoside G (UMHMNP147769504) and sarasinoside B1 (UMHMNP114066501).
During the simulations, these four candidates maintained stable interactions with crucial amino acid residues inside the protein cavity, such as threonine 435 and asparagine 436. Furthermore, embedding the protein-ligand complexes within a simulated lipid bilayer membrane environment did not disrupt their binding affinity, suggesting that the structural stability holds firm in conditions that mimic a real cell membrane.
What These Preliminary Findings Mean for Patients
While the computational metrics point to strong binding potential, the authors emphasize that these results are strictly preliminary. Computer models alone cannot distinguish whether a compound acts as a true inhibitor that blocks the pump or merely as a transported substrate that the protein casually ejects.
Additionally, the current simulation model did not incorporate cholesterol, a vital cell membrane component known to influence how ABC transporters function. Future research will require laboratory experiments, including biochemical transport assays and cell-based testing, to confirm whether these marine natural products can safely and effectively overcome drug resistance in a clinical setting.
The research was published in Royal Society open science on November 18, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Abdelrahman, Alaa H. M.., et al. “In silico identification of marine natural products as potential ABCG2 ligands.” Royal Society Open Science, vol. 13, no. 11, November 18, 2026 The Royal Society, doi: 10.1098/rsos.261017. <https://doi.org/10.1098/rsos.261017>.
Cite this page:
- Posted by David Anderson